As of March 2026, Gilead Sciences (NASDAQ: GILD) stands at a critical inflection point in its corporate evolution. Historically defined by its dominance in the antiviral market—specifically HIV and Hepatitis C—Gilead has spent the last five years aggressively pivoting toward a diversified biopharmaceutical model with oncology as its secondary pillar. The linchpin of this strategy is Trodelvy (sacituzumab govitecan), a first-in-class Trop-2 directed antibody-drug conjugate (ADC).
This report evaluates Gilead’s progress in reducing its “antiviral dependency,” the commercial trajectory of Trodelvy across breast and lung cancer indications, and the long-term viability of its oncology expansion. While HIV remains the primary cash flow driver, contributing over 70% of product sales in 2025, the oncology segment’s 2025 revenue reached approximately $3.2 billion, signaling a maturing portfolio that is beginning to balance the company’s historical volatility.
Table of Contents
1. Portfolio Diversification: Breaking the Antiviral Monopoly
For over a decade, Gilead’s valuation was tethered almost exclusively to its HIV franchise. While products like Biktarvy continue to command >50% market share in the U.S., the emergence of patent cliffs and the saturation of the HIV treatment market necessitated a structural shift.
The Revenue Mix Shift (2021 vs. 2025)
In 2021, Gilead’s oncology sales were a mere fraction of total revenue. By the end of fiscal year 2025, the landscape had shifted:
- Total Product Sales (2025): $28.9 billion.
- HIV Portfolio: $20.8 billion (approx. 72% of sales).
- Oncology (Trodelvy + Cell Therapy): $3.2 billion (approx. 11% of sales).
- Liver Disease & Other: $4.9 billion.
While 11% may seem modest, the Growth Velocity is the key metric. Trodelvy sales grew 6% in 2025 to $1.4 billion, despite the strategic withdrawal from the bladder cancer indication. More importantly, the oncology pipeline now represents over 50% of Gilead’s Phase 3 clinical trials, suggesting that the “Third of Revenue from Oncology by 2030” goal remains a feasible, if ambitious, target.
2. Trodelvy Performance Analysis: The ADC Powerhouse
Trodelvy is the cornerstone of Gilead’s $21 billion acquisition of Immunomedics. Its performance in 2025 and early 2026 has been defined by clinical expansion into earlier lines of therapy.
Breast Cancer: Moving to Frontline
Trodelvy’s primary revenue drivers remain metastatic Triple-Negative Breast Cancer (mTNBC) and HR+/HER2- metastatic breast cancer.
- mTNBC Market Dominance: In January 2026, the NCCN Guidelines updated Trodelvy to a Category 1 preferred first-line treatment for mTNBC (PD-L1 negative). This shift from second-line to first-line status is expected to significantly increase the total addressable market (TAM) in 2026.
- The ASCENT-04 Catalyst: Results published in early 2026 showed that Trodelvy in combination with Keytruda reduced the risk of death or progression by 35% in frontline PD-L1+ mTNBC. This positions Trodelvy not just as a niche player, but as a “backbone” therapy for the most aggressive breast cancer subtype.
Lung Cancer (NSCLC): The Next Frontier
The expansion into Non-Small Cell Lung Cancer (NSCLC) has been more complex. While 2024 saw some setbacks in the EVOKE-01 trial, Gilead’s refined strategy in 2025 focused on:
- Biomarker Refinement: Targeting “high Trop-2 expressors” has improved clinical outcomes, allowing Gilead to maintain a competitive edge against AstraZeneca’s rival ADC, datopotamab deruxtecan (Dato-DXd).
- Combination Strategies: In 2026, the market is closely watching Phase 3 data for Trodelvy + Pembrolizumab in first-line NSCLC. If successful, lung cancer could eventually eclipse breast cancer as Trodelvy’s largest revenue source by 2028.
3. Financial Health and Investor Sentiment
Gilead’s Q4 2025 earnings reported an EPS of $1.86 and revenue of $7.93 billion, both exceeding consensus. However, the stock (GILD) has seen volatility, reflecting a “show me” attitude from investors regarding the cell therapy segment.
The Cell Therapy Drag
While Trodelvy has thrived, Gilead’s cell therapy unit (Kite) faced headwinds in 2025. Yescarta and Tecartus sales declined by 7% for the full year due to intensifying competition from bispecific antibodies and new CAR-T entrants. This puts more pressure on Trodelvy to carry the oncology growth narrative.
2026 Guidance and Valuation
- Projected 2026 Sales: $29.6B – $30.0B.
- Dividend Yield: Gilead remains a “Cash Flow Machine,” increasing its dividend by 3.8% in February 2026 to $0.82 per share.
- Valuation Multiples: Currently trading at a forward P/E that suggests the market still values Gilead as a “legacy” HIV company rather than a high-growth oncology player. Any significant “beat and raise” in Trodelvy sales in 1H 2026 could trigger a re-rating of the stock.
4. Risks and Competitive Landscape
The oncology pivot is not without significant risk:
- ADC Competition: The ADC space is the most crowded in oncology. AstraZeneca/Daiichi Sankyo (Dato-DXd) and Merck (MK-2870) are direct competitors to Trodelvy’s Trop-2 mechanism.
- Medicare Part D Redesign: This policy shift created a $900 million headwind in 2025. While Gilead has managed the impact, ongoing drug pricing negotiations under the Inflation Reduction Act (IRA) remain a long-term risk for high-priced biologics.
- Pipeline Concentration: With the failure of magrolimab (CD47) in 2024, Trodelvy now carries an outsized portion of Gilead’s oncology valuation.
5. Conclusion: A Multi-Year Transformation
Gilead Sciences is successfully executing the first phase of its oncology transformation. The company has moved from 0% oncology revenue to a multibillion-dollar segment in five years. While the reliance on the HIV portfolio (Biktarvy) remains high, the quality of that reliance has changed: HIV now acts as the “utility” business—stable, high-margin, and cash-generative—providing the capital necessary to fund the “growth” business of oncology.
For investors, 2026 is the year where “indication expansion” must turn into “market share dominance.” If Trodelvy can successfully capture the frontline mTNBC market and secure a foothold in NSCLC, Gilead will finally shed its label as a one-trick antiviral pony.